Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02183909 · ClinicalTrials.gov registry record · NA

Connecting Resources for Urban Sexual Health

A NA study of HIV and Sexually Transmitted Infections, sponsored by University of California, San Francisco.

Completed
Registry status
NA
Development phase
378
Enrollment target
1
Study location

NCT02183909 is a NA study of HIV and Sexually Transmitted Infections that has completed, run by University of California, San Francisco. The registered enrollment target is 378 participants, below the 439-participant average among 303 other HIV trials with a reported enrollment target (14% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02183909, a NA study of HIV and Sexually Transmitted Infections, has completed, sponsored by University of California, San Francisco.

COMPLETED
Registry status
NA
Development phase
378 participants
Enrollment target
1
Study location

Study Summary

The overall goal of the CRUSH project is to enhance and extend a response to the local HIV/AIDS epidemic in Alameda County with a set of innovative, evidence-based interventions across the continuum of HIV prevention and care, targeting individuals and communities most vulnerable to HIV. The East Bay AIDS Center, in partnership with the University of California San Francisco's Center for AIDS Prevention Studies, the Gladstone Institutes, and several key community-based organizations, are engaging in a participatory partnership to enhance and implement HIV services which target the East Bay's highest risk population- young men who have sex with men (Y/MSM). Specifically, the CRUSH Project is designed to evaluate a combination of program approaches to address the sexual health care needs of young gay men of color and their sexual partners by enhancing the current program activities of the Downtown Youth Clinic (DYC). We hypothesize that we can reduce the impact of HIV among Y/MSM by expanding the current DYC services structure in two ways. We intend to expand HIV testing, and linkage to and retention in care for youth who test HIV positive, providing them with intensive risk-reduction counseling and antiretroviral treatment, and thereby ultimately reducing the risk of further HIV transmission. And we intend for the first time to offer a comprehensive combination package of preventive services to HIV-negative youth, including routine accesses to HIV/STI screening and treatment, and access to HIV pre-exposure prophylaxis (PrEP). The CRUSH Project will also have a substudy that will enroll HIV-negative participants who are eligible to receive PEP. The substudy will evaluate the tolerability and acceptability of a 28 day course of Stribild® given as post-exposure prophylaxis (PEP) to prevent sexual acquisition of HIV-1 in Y/MSM of color.

Interventions

  • OTHER Testing and linkage to care for Y/MSM
  • BEHAVIORAL Engagement and retention for HIV-positive Y/MSM in care
  • OTHER Engagement and retention for HIV-negative Y/MSM in sexual health services
  • DRUG Stribild PEP Substudy

Study Locations (1)

California

  • Downtown Youth Clinic - Oakland

Trial Details

FieldValue
Enrollment Target 378 participants
Start Date 2013-05
Est. Completion 2017-08
Phase NA

What the Registry Record Tells You About NCT02183909

The ClinicalTrials.gov registry entry for NCT02183909 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 378 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 439-participant average among 303 other HIV trials with a reported enrollment target (14% lower). The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with HIV appearing as the primary indexed condition, and to 4 interventions - of which Testing and linkage to care for Y/MSM is the first listed.

NCT02183909 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT02183909 about?

NCT02183909 is a clinical study titled "Connecting Resources for Urban Sexual Health". The overall goal of the CRUSH project is to enhance and extend a response to the local HIV/AIDS epidemic in Alameda County with a set of innovative, evidence-based interventions across the continuum of HIV prevention and care, targeting individuals and communities most vulnerable to HIV. The East Ba...

What is the current status of trial NCT02183909?

This trial is currently completed. It is a NA study. The enrollment target is 378 participants. The study started on 2013-05. Estimated completion is 2017-08.

What conditions does trial NCT02183909 study?

This clinical trial studies the following conditions: HIV, Sexually Transmitted Infections.

What interventions are being tested in trial NCT02183909?

The interventions under investigation include: Testing and linkage to care for Y/MSM (OTHER), Engagement and retention for HIV-positive Y/MSM in care (BEHAVIORAL), Engagement and retention for HIV-negative Y/MSM in sexual health services (OTHER), Stribild PEP Substudy (DRUG).

Who is sponsoring clinical trial NCT02183909?

This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02183909 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for HIV

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.